Explainer
Cystic fibrosis explained: the CFTR gene and modulator drugs
Cystic fibrosis is an inherited disease in which thick, sticky mucus damages the lungs, digestive system and other organs. It is caused by inheriting two faulty copies of the CFTR gene.[1][2] Once considered a fatal disease of childhood, it now allows many people to live well into adulthood thanks to better treatment.[3] CFTR modulator drugs, including ivacaftor (approved in 2012), make the faulty protein work better; NHLBI says the triple combination may help up to 90% of patients, but they do not work for every mutation.[4][5][6]
This page explains cystic fibrosis and its treatments. It is not medical advice. Decisions about testing and treatment belong with a cystic fibrosis care team. This page gives no dosing information.
Cystic fibrosis is an inherited disease in which the body makes thick, sticky mucus that can damage many organs. Its most common effects are progressive lung damage and long-term digestive problems.[1]
The CFTR gene
People who inherit two mutated copies of the CFTR gene, one from each parent, have cystic fibrosis. The faulty CFTR protein disrupts the movement of salt and water in and out of cells, so mucus becomes thick and sweat becomes extra salty.[2]
Someone with one faulty copy is a carrier and usually has no symptoms. If two carriers have a baby, there is a 1 in 4 chance the child has cystic fibrosis and a 2 in 4 chance the child is a carrier.[7]
More than 2,000 CFTR mutations can cause cystic fibrosis. With the most common one, the protein cannot hold its correct shape; other mutations mean cells make little CFTR protein at all.[8] Which mutations a person carries determines whether a modulator is likely to work.[6]
In the US the disease occurs in 1 in 2,500 to 3,500 white newborns, about 1 in 17,000 African American newborns and 1 in 31,000 Asian American newborns.[9]
Symptoms and complications
Symptoms include a cough that brings up mucus, wheezing, frequent chest and sinus infections, digestive problems, slow growth in children and very salty sweat.[10] Over time, mucus and repeated infections can permanently damage the lungs. Mucus also often damages the pancreas, so it makes less insulin and fewer digestive enzymes.[11] Most men with cystic fibrosis have congenital bilateral absence of the vas deferens, in which the tubes that carry sperm do not develop properly, causing infertility unless they have fertility treatment.[12]
Diagnosis
In the UK every baby is checked through the newborn blood spot test. If the result suggests cystic fibrosis, a sweat test measuring salt confirms it.[13]
Standard care
There is no cure.[14] Care focuses on clearing the airways, with antibiotics for infections, medicines that open the airways or loosen mucus, nutritional support and, for some people with severe lung disease, a lung transplant.[14] Cystic fibrosis was once considered a fatal disease of childhood; with better treatment, many people now live well into adulthood.[3]
CFTR modulators
CFTR modulators are oral medicines that make faulty CFTR proteins work better and help with lung function. They only work for certain mutations, so genetic testing comes first.[6]
- 2012: the FDA approved ivacaftor (Kalydeco).[4]
- 2019: the FDA approved the triple combination elexacaftor-tezacaftor-ivacaftor (Trikafta).[15] NHLBI says it may help up to 90% of people with cystic fibrosis and is approved from age 2 for certain mutations.[5]
- 2024: the FDA approved Alyftrek, a combination of vanzacaftor, tezacaftor and deutivacaftor.[16]
Not everyone benefits. NHLBI says people who are Asian, Black or Hispanic are more likely to have mutations that do not respond to the available modulators.[17]
Like sickle cell disease, cystic fibrosis is an autosomal recessive condition picked up by newborn screening in the UK.[18][19][13]
Read next
Coeliac disease explained: symptoms, diagnosis and gluten-free labels
What coeliac (celiac) disease is, who gets it, how it is diagnosed, why the treatment is a lifelong gluten-free diet, and what a US "gluten-free" label means.
Questions readers ask
How do you get cystic fibrosis?
It is inherited. A child must get a faulty CFTR gene from each parent. If two carriers have a baby, there is a 1 in 4 chance the child has cystic fibrosis and a 2 in 4 chance the child is a carrier.[2][7]
What are the symptoms of cystic fibrosis?
A cough that brings up mucus, frequent chest and sinus infections, digestive problems, slow growth in children and very salty sweat.[10]
How is it diagnosed?
In the UK all babies are checked through the newborn blood spot test, and a sweat test that measures salt confirms the diagnosis.[13]
What are CFTR modulators?
Oral medicines that make the faulty CFTR protein work better. They only work for certain mutations, so genetic testing comes first. NHLBI says the triple combination elexacaftor-tezacaftor-ivacaftor may help up to 90% of people with cystic fibrosis.[6][5]
Why can't everyone take a modulator?
Modulators work only for certain CFTR mutations, and NHLBI says people who are Asian, Black or Hispanic are more likely to have mutations that do not respond to them.[6][17]
Is there a cure?
No. Treatment eases symptoms with airway clearance, antibiotics, airway medicines and nutritional support, and some people need a lung transplant.[14]
Sources
· 19 claims from 4 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Cystic fibrosis is an inherited disease in which thick, sticky mucus builds up and damages many organs, most often the lungs and digestive system. confirmedas of 2026-11-07
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- [2]
Cystic fibrosis is caused by inheriting two mutated copies of the CFTR gene; the faulty CFTR protein disrupts how salt and water move in and out of cells, making mucus thick and sweat extra salty. confirmedas of 2026-11-07
- Cystic Fibrosis: Causes and Risk Factors · National Heart, Lung, and Blood Institute (NIH) · Primary source · Causes (retrieved 2026-11-07)
- Cystic Fibrosis: Causes and Risk Factors · National Heart, Lung, and Blood Institute (NIH) · Primary source · How do CFTR mutations cause cystic fibrosis? (retrieved 2026-11-07)
- [3]
Cystic fibrosis was once considered a fatal disease of childhood, but with improved treatment many people now live well into adulthood. confirmedas of 2026-11-07
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- [4]
The FDA first approved ivacaftor (Kalydeco, NDA 203188), a CFTR modulator, on 31 January 2012. confirmedas of 2012-01-31
- Drugs@FDA record for KALYDECO (NDA 203188), via openFDA · U.S. Food and Drug Administration · Primary source · submissions, ORIG 1 (retrieved 2026-11-07)
- Drugs@FDA record for KALYDECO (NDA 203188), via openFDA · U.S. Food and Drug Administration · Primary source · openfda application_number (retrieved 2026-11-07)
- [5]
NHLBI says the triple combination elexacaftor-tezacaftor-ivacaftor may help up to 90% of people with cystic fibrosis and is approved from age 2 for certain mutations. confirmedas of 2026-11-07
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- [6]
CFTR modulators are oral medicines that make faulty CFTR proteins work better, but they only work for certain mutations, so genetic testing comes first. confirmedas of 2026-11-07
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- [7]
A person with one altered CFTR gene is a carrier without symptoms; if two carriers have a child, there is a 1 in 4 chance the child has cystic fibrosis, a 2 in 4 chance the child is a carrier and a 1 in 4 chance of neither. confirmedas of 2026-11-07
- Cystic fibrosis · NHS · Primary source · Causes (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Causes (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Causes (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Causes (retrieved 2026-11-07)
- [8]
More than 2,000 CFTR mutations can cause cystic fibrosis; with the most common one, the protein cannot hold its correct shape, while some others leave cells making hardly any CFTR protein. confirmedas of 2026-11-07
- Cystic Fibrosis: Causes and Risk Factors · National Heart, Lung, and Blood Institute (NIH) · Primary source · How do CFTR mutations cause cystic fibrosis? (retrieved 2026-11-07)
- Cystic Fibrosis: Causes and Risk Factors · National Heart, Lung, and Blood Institute (NIH) · Primary source · How do CFTR mutations cause cystic fibrosis? (retrieved 2026-11-07)
- Cystic Fibrosis: Causes and Risk Factors · National Heart, Lung, and Blood Institute (NIH) · Primary source · How do CFTR mutations cause cystic fibrosis? (retrieved 2026-11-07)
- [9]
In the US cystic fibrosis occurs in 1 in 2,500 to 3,500 white newborns, about 1 in 17,000 African Americans and 1 in 31,000 Asian Americans. confirmedas of 2026-11-07
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Frequency (retrieved 2026-11-07)
- [10]
Symptoms include a persistent cough with mucus, wheezing, frequent chest infections, digestive problems, poor growth in children and very salty sweat. confirmedas of 2026-11-07
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · Symptoms (retrieved 2026-11-07)
- [11]
Mucus buildup and infections can cause permanent lung damage over time, and mucus often damages the pancreas, impairing its production of insulin and digestive enzymes. confirmedas of 2026-11-07
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- [12]
Most men with cystic fibrosis have congenital bilateral absence of the vas deferens, in which the tubes that carry sperm do not develop properly, causing infertility unless they have fertility treatment. confirmedas of 2026-11-07
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- Cystic fibrosis (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- [13]
All babies in the UK are checked for cystic fibrosis through the newborn blood spot test, and a sweat test that measures salt confirms the diagnosis. confirmedas of 2026-11-07
- Cystic fibrosis · NHS · Primary source · How cystic fibrosis is diagnosed (retrieved 2026-11-07)
- Cystic fibrosis · NHS · Primary source · How cystic fibrosis is diagnosed (retrieved 2026-11-07)
- [14]
There is no cure; care includes airway clearance, antibiotics, medicines to open the airways or thin mucus, nutritional support and, for some, a lung transplant. confirmedas of 2026-11-07
- Cystic fibrosis · NHS · Primary source · Treatments (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Treatment (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Surgery (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Medicines (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Medicines (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Medicines (retrieved 2026-11-07)
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · Treatment (retrieved 2026-11-07)
- [15]
The FDA approved the triple combination Trikafta (NDA 212273) on 21 October 2019. confirmedas of 2019-10-21
- Drugs@FDA record for TRIKAFTA (NDA 212273), via openFDA · U.S. Food and Drug Administration · Primary source · submissions, ORIG 1 (retrieved 2026-11-07)
- Drugs@FDA record for TRIKAFTA (NDA 212273), via openFDA · U.S. Food and Drug Administration · Primary source · openfda application_number (retrieved 2026-11-07)
- [16]
The FDA approved Alyftrek (NDA 218730), a combination of vanzacaftor, tezacaftor and deutivacaftor, on 20 December 2024. confirmedas of 2024-12-20
- Drugs@FDA record for ALYFTREK (NDA 218730), via openFDA · U.S. Food and Drug Administration · Primary source · submissions, ORIG 1 (retrieved 2026-11-07)
- Drugs@FDA record for ALYFTREK (NDA 218730), via openFDA · U.S. Food and Drug Administration · Primary source · products, active_ingredients (retrieved 2026-11-07)
- Drugs@FDA record for ALYFTREK (NDA 218730), via openFDA · U.S. Food and Drug Administration · Primary source · products, active_ingredients (retrieved 2026-11-07)
- Drugs@FDA record for ALYFTREK (NDA 218730), via openFDA · U.S. Food and Drug Administration · Primary source · products, active_ingredients (retrieved 2026-11-07)
- Drugs@FDA record for ALYFTREK (NDA 218730), via openFDA · U.S. Food and Drug Administration · Primary source · openfda application_number (retrieved 2026-11-07)
- [17]
People who are Asian, Black or Hispanic are more likely to have mutations that do not respond to available CFTR modulators. confirmedas of 2026-11-07
- Cystic Fibrosis: Treatment · National Heart, Lung, and Blood Institute (NIH) · Primary source · CFTR modulators (retrieved 2026-11-07)
- [18]
Sickle cell disease is caused by variants in the HBB gene, which makes beta-globin, and is inherited in an autosomal recessive pattern; sickle cell anaemia (HbSS), in which hemoglobin S replaces both beta-globin subunits, is the most common form, while in other forms one subunit is hemoglobin S and the other a different version such as hemoglobin C. confirmedas of 2026-11-07
- Sickle cell disease (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Causes (retrieved 2026-11-07)
- Sickle cell disease (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Inheritance (retrieved 2026-11-07)
- Sickle cell disease (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Causes (retrieved 2026-11-07)
- Sickle cell disease (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Causes (retrieved 2026-11-07)
- [19]
In the UK sickle cell disease is usually found through pregnancy and newborn screening, including the newborn heel-prick blood spot test. confirmedas of 2026-11-07
- Sickle cell disease · NHS · Primary source · How sickle cell disease is diagnosed (retrieved 2026-11-07)
- Sickle cell disease · NHS · Primary source · Screening for sickle cell disease in babies (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: May 7, 2027.
Cite this page
"Cystic fibrosis explained: the CFTR gene and modulator drugs." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/cystic-fibrosis-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.